Growth hormone releasing hexapeptide
|This article's factual accuracy is disputed. (March 2013)|
||This article needs attention from an expert in Medicine. (March 2013)|
|Growth hormone releasing hexapeptide|
|Jmol-3D images||Image 1|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
Growth hormone releasing hexapeptide (GHRP6) is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids, were developed for their growth hormone (GH) releasing activity and are called GH secretagogues. They lack opioid activity but are potent stimulators of GH release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through action at a completely different receptor. This receptor was originally called the GH secretagogue receptor, but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand. Therefore, these GH secretagogues act as synthetic ghrelin mimetics.
It has also been discovered that when GHRP-6 and insulin are used simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.
GH secretagogues differ from exogenous rHGH in their effects primarily due to the fact that endogenous GH contains all 5 isoforms of growth hormone, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot. Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma IGF1 levels.
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (September 2011)|
- Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB (2004). "Ghrelin--a hormone with multiple functions". Frontiers in neuroendocrinology 25 (1): 27–68. doi:10.1016/j.yfrne.2004.03.002. PMID 15183037.
- Peñalva, A; Carballo, A; Pombo, M; Casanueva, FF; Dieguez, C (1993). "Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man". The Journal of Clinical Endocrinology and Metabolism 76 (1): 168–71. doi:10.1210/jc.76.1.168. PMID 8421084.
- Camanni, F; Ghigo, E; Arvat, E (1998). "Growth hormone-releasing peptides and their analogs". Frontiers in neuroendocrinology 19 (1): 47–72. doi:10.1006/frne.1997.0158. PMID 9465289.
- Adeghate, E; Ponery, AS (2002). "Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats". Journal of neuroendocrinology 14 (7): 555–60. doi:10.1046/j.1365-2826.2002.00811.x. PMID 12121492.
- McGirr, R; McFarland, MS; McTavish, J; Luyt, LG; Dhanvantari, S (2011). "Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a". Regulatory peptides 172 (1-3): 69–76. doi:10.1016/j.regpep.2011.08.011. PMID 21893106.
- Koh, B., & Hardie, M. (2013). We need an advocate against ASADA’s power in doping control. Retrieved from https://theconversation.edu.au/we-need-an-advocate-against-asadas-power-in-doping-control-12119